After Alnylam (ALNY) partner The Medicine Co. (MDCO) presented Phase 3 data on inclisiran at the European Society of Cardiology Congress, Stifel analyst Paul Matteis said the efficacy data were positive, but the focus is really on safety and "encouragingly" the adverse events, incidence of death, and serious adverse events all occurred at similar rates on inclisiran versus placebo. The analyst, who believes the data broadly support inclisiran as an approvable drug, also thinks the results validate Alnylam's recent efforts in non-orphan areas. Matteis, who noted that Alnylam will receive up to a 20% royalty on inclisiran sales, has a Buy rating and $116 price target on Alnylam shares.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).